Quick Answer
Serina Therapeutics, Inc. reported Operating Income of -$24.02 million for fiscal year 2025.
Serina Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$24.02M | -40.9% |
| 2024 | -$17.05M | -444.8% |
| 2023 | -$3.13M | +55.1% |
| 2022 | -$6.97M | +12.1% |
| 2021 | -$7.93M | +21.5% |
| 2020 | -$10.10M | +19.6% |
| 2019 | -$12.56M | -11.7% |
| 2018 | -$11.24M | -68.8% |
| 2017 | -$6.66M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$6.39M | -20.3% | -14.9% |
| June 30, 2025 | -$5.57M | -43.9% | +5.0% |
| March 31, 2025 | -$5.86M | -152.4% | -10.3% |
| September 30, 2024 | -$5.31M | -263.1% | -37.4% |
| June 30, 2024 | -$3.87M | -309.1% | -66.6% |
| March 31, 2024 | -$2.32M | -141.3% | -58.6% |
| September 30, 2023 | -$1.46M | +5.6% | -54.8% |
| June 30, 2023 | -$945.0K | +40.6% | +1.8% |
- Serina Therapeutics, Inc. showed a decrease of -40.9% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, Serina Therapeutics, Inc.’s operating income has declined by 260.5% (from -$6.66 million to -$24.02 million).
- The most recent figure is from Serina Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: